Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status

Neoplasma

Volumn 59, Issue 1, 2012, Pages 85-91

  Krasteva, M E ^a   Bozhanov, S S ^a   Antov, G G ^a   Gospodinova, Z I ^a   Angelova, S G ^a   Georgieva, E I ^a  

^a INSTITUTE OF PHYSIOLOGY   (Bulgaria)

Author keywords

BRCA1; Breast cancer; Clinicopathological characteristics; Hypermethylation; Overall survival

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; DNA ISOLATION; DNA METHYLATION; FEMALE; GENETIC ASSOCIATION; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROMOTER REGION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; BREAST TUMOR; BULGARIA; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; GENETICS; KAPLAN MEIER METHOD; LUNG CARCINOMA; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROTO ONCOGENE;

ADULT; AGED; BREAST NEOPLASMS; BULGARIA; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL CYCLE PROTEINS; CHI-SQUARE DISTRIBUTION; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENES, BRCA1; GENES, ERBB-2; GENES, P53; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEINS;

EID: 84863769439     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_011     Document Type: Article

References (39)

1. VALERIANOVA Z, VUKOV M, DIMITROVA N editors. Cancer incidence in Bulgaria 2006. Sofia: AVIS-24 Ltd., 2008.
2. HALL JM, LEE MK, NEWMAN B, MORROW JE, ANDERSON LA et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684-1689. http://dx.doi.org/10.1126/science.2270482
3. MIKI Y, SWENSEN J, SHATTUCK-EIDENS D, FUTREAL PA, HARSHMAN K et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71. http://dx.doi.org/10.1126/science.7545954
4. DENG CX, WANG RH Roles of BRCA1 in DNA damage repair: a link between development and cancer. Human Molecular Genetics 2003; 12, Review Issue 1: 113-123.
5. XU B, KIM S, KASTAN MB Involvement of Brca1 in S-phase and G (2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001; 21: 3445-3450. http://dx.doi.org/10.1128/MCB.21.10.3445-3450.2001
6. HARKIN DP, BEAN JM, MIKLOS D, SONG YH, TRUONG VB et al. Induction of GADD45 and JNK/SAPK dependent apoptosis following inducible expression of BRCA1. Cell 1999; 97: 575-586. http://dx.doi.org/10.1016/S0092-8674(00)80769-2
7. SHUKLA V, COUMOUL X, LAHUSEN T, WANG RH, XU X et al. BRCA1 affects global DNA methylation through regulation of DNMT1. Cell Res 2010; 20: 1201-1215. http://dx.doi. org/10.1038/cr.2010.128
8. THOMPSON ME, JENSEN RA, OBERMILLER PS, PAGE DL, HOLT JT Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9: 444-450. http://dx.doi. org/10.1038/ng0495-444
9. SAKAI T, TOGUCHIDA J, OHTANI N, YANDELL DW, RAPAPORT JM et al. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991; 48: 880-888.
10. HERMAN JG, LATIF F, WENG Y, LERMAN MI, ZBAR B et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-9704. http://dx.doi.org/10.1073/pnas.91.21.9700
11. HILTUNEN MO, ALHONEN L, KOISTINAHO J, MYOHANEN S, PAAKKONEN M et al. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int J Cancer 1997; 70: 644-648. http://dx.doi.org/10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.0.CO;2-V
12. AI L, VO QN, ZUO C, LI L, LING W et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev 2004; 13: 150-156. http://dx.doi.org/10.1158/1055-9965.EPI-082-3
13. DOBROVIC A, SIMPFENDORFER D Methylation of the BRCA1 Gene in Sporadic Breast Cancer. Cancer Res 1997; 57: 3347-3350.
14. BIANCO T, CHENEVIX-TRENCH G, WALSH DC, COOPER JE, DOBROVIC A Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 2000; 21: 147-151. http://dx.doi.org/10.1093/carcin/21.2.147
15. ESTELLER M, SILVA JM, DOMINGUEZ G, BONILLA F, MATIAS-GUIU X et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-569. http://dx.doi.org/10.1093/jnci/92.7.564
16. RICE JC, MASSEY-BROWN KS, FUTSCHER BW Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998; 17: 1807-1812. http://dx.doi.org/10.1038/sj.onc.1202086
17. BOZHANOV SS, ANGELOVA SG, KRASTEVA ME, MARKOV TL, CHRISTOVA SL et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol 2010; 136: 1657-1669. http://dx.doi.org/10.1007/s00432-010-0824-9
18. BALDWIN RL, NEMETH E, TRAN H, SHVARTSMAN H, CASS I et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000; 60: 5329-5333.
19. BIRGISDOTTIR V, STEFANSSON OA, BODVARSDOTTIR SK, HILMARSDOTTIR H, JONASSON JG et al. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006; 8: R38. http://dx.doi. org/10.1186/bcr1522
20. CATTEAU A, HARRIS WH, XU CF, SOLOMON E Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999; 18: 1957-1965. http://dx.doi.org/10.1038/sj.onc.1202509
21. MATROS E, WANG ZC, LODEIRO G, MIRON A, IGLEHART JD et al. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 2005; 91: 179-186. http://dx.doi.org/10.1007/s10549-004-7603-8
22. BAGADI SA, PRASAD CP, KAUR J, SRIVASTAVA A, PRASHAD R et al. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients. Life Sci 2008; 82: 1288-1292. http://dx.doi.org/10.1016/j.lfs.2008.04.020
23. CHEN Y, ZHOU J, XU Y, LI Z, WEN X et al. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer. Cancer Sci 2009; 100: 1663-1667. http://dx.doi.org/10.1111/j.1349-7006.2009.01225.x
24. WEI M, GRUSHKO TA, DIGNAM J, HAGOS F, NANDA R et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 2005; 65: 10692-10699. http://dx.doi.org/10.1158/0008-5472.CAN-05-1277
25. NIWA Y, OYAMA T, NAKAJIMA T BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Jpn J Cancer Res 2000; 91: 519-526.
26. JING F, ZHANG J, TAO J, ZHOU Y, JUN L et al. Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie 2007; 30: 14-19. http://dx.doi.org/10.1159/000096892
27. LI S, RONG M, IACOPETTA B DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 2006; 237: 272-280. http://dx.doi. org/10.1016/j.canlet.2005.06.011
28. KARRAY-CHOUAYEKH S, TRIFA F, KHABIR A, BOUJELBANE N, SELLAMI-BOUDAWARA T et al. Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma. J Biomed Biotechnol 2009; Vol 2009. http://dx.doi.org/10.1155/2009/369129
29. XU X, GAMMON MD, ZHANG Y, BESTOR TH, ZEISEL SH et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2009; 115: 397-404. http://dx.doi. org/10.1007/s10549-008-0075-5
30. MIRZA S, SHARMA G, PRASAD CP, PARSHAD R, SRIVASTAVA A et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007; 81: 280-287. http://dx.doi.org/10.1016/j.lfs.2007.05.012
31. TURNER N, TUTT A, ASHWORTH A Hallmarks of 'BRCAness' in sporadic cancers. Nature Reviews of Cancer 2004; 4: 814-819. http://dx.doi.org/10.1038/nrc1457
32. HILAKIVI-CLARKE L Estrogens, BRCA1, and breast cancer. Cancer Res 2000; 60: 4993-5001.
33. FAN S, WANG J, YUAN R, MA Y, MENG Q et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284: 1354-1356. http://dx.doi.org/10.1126/science.284.5418.1354
34. FAN S, MA YX, WANG C, YUAN RQ, MENG Q et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001; 20: 77-87. http://dx.doi.org/10.1038/sj.onc.1204073
35. DIAN D, HEROLD H, MYLONAS I, SCHOLZ C, JANNI W et al. Survival analysis between patients with invasive ductal and invasive lobular breast cancer. Arch Gynecol Obstet 2009; 279: 23-28. http://dx.doi.org/10.1007/s00404-008-0662-z
36. PETITJEAN A, ACHATZ MI, BORRESEN-DALE AL, HAINAUT P, OLIVIER M TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165. http://dx.doi. org/10.1038/sj.onc.1210302
37. OLIVIER M, LANGEROD A, CARRIERI P, BERGH J, KLAAR S et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12: 1157-1167. http://dx.doi.org/10.1158/1078-0432.CCR-05-1029
38. LANGEROD A, ZHAO H, BORGAN O, NESLAND JM, BUKHOLM IR et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007; 9: R30. http://dx.doi.org/10.1186/bcr1675
39. STEFANSSON OA, JONASSON JG, OLAFSDOTTIR K, HILMARSDOTTIR H, OLAFSDOTTIR G et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 2011; 6:638-649. http://dx.doi.org/10.4161/epi.6.5.15667